Traditional prostate biopsy is an imperfect method for detecting prostate cancer. Fusion biopsy is an emerging biopsy technique that combines multiparametric magnetic resonance imaging (mpMRI) with real-time ultrasound-guided biopsy to target suspicious areas seen on MRI. During a fusion biopsy, the radiologist performs a mpMRI of the prostate prior to the biopsy. This MRI provides detailed images of the prostate gland and any suspicious lesions.

Fusion Biopsy in the ultrasound machine is integrated with software that allows the radiologist to visualize the previously acquired MRI images alongside the real-time ultrasound images. This allows the radiologist to precisely target any areas that were suspicious on MRI. Biopsy cores are taken from these targeted areas under ultrasound guidance.

In the fusion biopsy combines the functional imaging abilities of mpMRI with the tissue sampling of real-time ultrasound-guided biopsy to target suspicious prostate lesions. This targeted approach detects more clinically significant cancers compared to standard biopsy, particularly higher grade and higher stage tumors. Fusion biopsy also reduces unnecessary biopsies of insignificant cancers while lowering risks from reduced biopsy cores. Continued technological enhancements together with growing clinical adoption will allow fusion biopsy to transform prostate cancer diagnosis.

Get more insights on, Fusion Biopsy

Explore More Related Article On- Gene Therapy Market